YUMAB® Antibody Libraries

YUMAB’s universal human antibody libraries with more than 100 billion unique antibodies and advanced in vitro selection technologies provide highest success rates from the start for your antibody development program.

YUMAB® libraries contain naturally derived antibody sequences (no synthetic sequences) based on the close to germline repertoire. These sequences are pre-selected in the human body for low toxicity, immunogenicity and high productivity.

Platform_Technologies_1_Library technologies_Bild1

YUMAB® libraries have a long track record and have proven their value and excellent quality in pharmaceutical pipelines when compared head-to-head with other commercial libraries.

YUMAB® Antibody Library Features

  • Universal, reliable and robust
  • Nature-derived antibody repertoires
  • Large epitope coverage and high hit rates
  • Flexible business conditions

References – YUMAB® libraries

Miethe, S., Mazuet, C., Liu, Y., Tierney, R., Rasetti-Escargueil, C., Avril, A., Frenzel, A., Thullier, P., Pelat, T., Urbain, R., Fontayne, A., Sesardic, D., Hust, M. and Popoff, M.-R. (2016). Development of Germline-Humanized Antibodies Neutralizing Botulinum Neurotoxin A and B. PLoS ONE 11: e0161446 (PubMed)

Schieferdecker, A., Oberle, A., Thiele, B., Hofmann, F., Göthel, M, Miethe, S., Hust, M., Braig, F., Voigt, M., Koch-Nolte, F., Haag, F., Alawi, M., Indenbirken, D., Grundhoff, A., Bokemeyer, C., Bacher, U., Kröger, N. and Binder, M. (2016). A transplant immunome deep sequencing and screening platform defines a unique targetable epitope fingerprint of multiple myeloma. Blood 127: 3202-3214 (PubMed)

Kügler, J., Wilke, S. Meier, D., Tomszak, F.,  Frenzel, A. , Schirrmann, T., Dübel, S.,  Garritsen, H.,  Hock, B., Toleikis, L., Schütte, M. & Hust, M. (2015). Generation and analysis of the improved human HAL9/10 antibody phage display libraries. BMC-Biotechnology 15: 10 (PubMed)

Frenzel, A., Kügler, J., Wilke, S., Schirrmann, T. & Hust, M. (2014). Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Molecular Biology 1060: 215-243 (PubMed)

Miethe, S., Rasetti-Escargueil, C., Liu, Y., Chahboun, S., Pelat, T., Avril, A., Frenzel, A., Schirrmann, T., Thullier, P., Sesardic, D. & Hust, M. (2014). Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. mAbs 6: 446-459 (PubMed)

Hust, M., Meyer, T., Voedisch, B., Rülker, T., Thie, H., Schütte, M., Helmsing, S., Meier, D., Schirrmann, T. & Dübel, S. (2011). A human scFv antibody generation pipeline for proteome research, Journal of Biotechnology 152,159-170 (PubMed)

Thie, H., Toleikis, L., Li, J., von Wasielewski, R., Bastert, G., Schirrmann, T., Esteves, I. T., Behrens, C. K., Fournes, B., Fournier, N., de Romeuf, C., Hust, M. and Dübel, S. (2011). Rise and fall of an anti-MUC1 specific antibody. PLoS ONE 6: e15921 (PubMed)

Pelat, T., Hust, M., Laffly. E., Condemine, F., Bottex, C., Vidal, D., Lefranc, M.P., Dübel, S. & Thullier, P. (2007). A high affinity, human like antibody fragment (scFv) neutralising lethal factor (LF) of Bacillus anthracis by inhibiting the PA-LF complex formation. Antimicrobial agents and chemotherapy 51, 2758-2764 (PubMed)


Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany

Email: info@yumab.com
Phone: +49 531 481170-0